Despite decades of research, treatment options are limited in the ARDS market. There are only a few treatments available in the ARDS market. The mainstay of management remains supportive care with mechanical ventilation. Other ARDS treatment options for patients include supplemental oxygen, prone positioning, the use of paralytics, fluid management, and a technique known as positive end-expiratory pressure (PEEP) to help push fluid out of air sacs. These are used in addition to ongoing ARDS treatment for the original disease or injury.
However, the dynamics of the ARDS market are expected to change in the coming years. Several leading pharma companies in the ARDS market are currently involved in developing novel therapies with distinct MoA to improve the treatment landscape.
As per the recently published Acute Respiratory Distress Syndrome (ARDS) Market Report by DelveInsight, the ARDS market size shall grow during the forecast period (2022–2032) owing to the launch of upcoming therapies and is expected to increase at a significant rate during the study period.
As per our estimates, the ARDS market size in seven major markets was approximately USD 1,173.1 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 10.31% for the study period (2019–2032).
DelveInsight estimates show that the United States accounts for the largest ARDS market size compared to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. The US contributed approximately USD 772.3 Million (65.8%) to the total ARDS market size of ARDS in the 7MM in 2021.
Among the EU5 countries, Germany had the highest market size, with approximately USD 166.2 million, followed by France in 2021. Moreover, the ARDS market size in Japan was valued at approximately USD 68.2 million in 2021. The ARDS market is expected to grow, mainly due to the increasing incident cases and the launch of upcoming therapy during the forecast period.
Key factors fueling the ARDS market growth
Several factors are driving the growth of the ARDS market. Among the prominent factors include rising ARDS prevalence, increasing R&D activities, the opportunistic market for emerging drugs, and others. Moreover, the increased ARDS market size is a direct result of the anticipated approval of new therapies and the growing patient population with acute respiratory distress syndrome in the 7MM. A detailed assessment of these factors is given below
Increasing ARDS prevalence and awareness
The rise in prevalence is the major factor contributing to the growth of the ARDS market. As per our analysis, there were approximately 1 million incident cases in the 7MM in 2021. These cases are expected to increase by 2032 at a CAGR of 1.5% during the study period 2019–2032. Thus, the growing patient population will create an opportunity for all the market leaders to develop novel treatment options to cater to the need of the patients, which will further boost the growth of the ARDS market in the coming years.
Additionally, the government is taking several measures and initiatives to make people aware of ARDS so that the number of undiagnosed and unreported cases will decrease and people will opt for medical treatment. Thus, the rising disease awareness is bolstering the ARDS marker size.
Rising cases of key indications
The major risk factors driving the ARDS prevalence are pneumonia, sepsis, aspiration, trauma, pancreatitis, COVID-19, and others. According to DelveInsight analysts, among the key indications, the highest cases were recorded for pneumonia (188K cases), followed by sepsis and trauma in the US in 2021. The increase in the cases of these indications will boost the ARDS market size. The trend of ARDS epidemiology is anticipated to be the same in the coming years.
COVID and its impact
COVID-19 emerged as another prominent risk factor for ARDS in 2020, in addition to existing risk factors. The pandemic has given enormous opportunities to key healthcare players, and so has in the ARDS treatment market. The rising prevalence and incidence of acute lung injury, a diverse set of risk factors for ARDS, and a rapid increase in the patient pool of covid-19 with ARDS drive the acute respiratory distress syndrome (ARDS) market.
Furthermore, the rising COVID-19-associated ARDS cases will give market players a lucrative opportunity to develop therapies targeting COVID-19-associated ARDS. The launch of these therapies will positively impact the global ARDS market.
Impact of emerging therapies in the ARDS market
The uptake of potential emerging ARDS therapies with a better clinical profile is expected to be high since no drug is approved. Several molecules are being evaluated and investigated by leading pharmaceutical goliaths such as MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others to strengthen the pipeline, thereby raising the hope for an efficacious therapy soon.
Currently, several assets in the ARDS pipeline are in the late and middle stages of development. The expected launch of emerging therapies, such as EB05 (Edesa Biotech/Light Chain Bio), DB-001 (Direct Biologics), BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys/Healios), Alteplase (Boehringer Ingelheim/Genentech), and Lucinactant (Windtree Therapeutics), etc. shall further create a positive impact on the ARDS market.
Furthermore, in April 2022, the FDA awarded ExoFlo a Regenerative Medicine Advanced Therapy (RMAT) designation. In July 2022, the company initiated the evaluation of the drug in phase III for COVID-19 moderate-to-severe ARDS. Another ARDS drug, MultiStem, is under development by Athersys and is currently in phase II/III stage for the treatment of COVID-19-induced ARDS. The FDA granted Fast Track designation to Athersys for its clinical program evaluating MultiStem cell therapy for the treatment of ARDS. Also, in September 2020, the FDA granted RMAT Designation to MultiStem Cell Therapy for the treatment of ARDS.
Hence, the ARDS pipeline is robust, with therapies in advanced stages of development with several designations. The availability of these therapies in the ARDS market will bring a ray of hope for the patients.
A rise in the MedTech segment
The global ARDS treatment market has expanded significantly in recent years and is predicted to proliferate in the future. Pharmaceutical and healthcare companies are rapidly evolving due to technological advancements, increased healthcare spending, and improved healthcare facilities and processes. Many hospitals, ambulatory surgical care facilities, and clinics throughout the world are implementing cutting-edge technology and equipment.
Furthermore, the increasing focus on drug discovery, rising demand for precision medicine, widespread use of home care settings and point-of-care diagnostics, and increased expenditures in R&D activities are likely to fuel global ARDS market growth during the forecast period.
Diagnostic devices such as capnography devices, spirometers, pulse oximeters, and blood gas analyzers aid in the early detection of acute respiratory distress, allowing proper therapy and treatment to be administered to patients, hence functioning as a significant driving factor in the ARDS market.
Currently, the leading MedTech companies working in the acute respiratory distress syndrome diagnostic segment include Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, and others along with some domestic players.
One of the primary causes of acute respiratory distress syndrome is air pollution. Vehicles are frequently responsible for harmful gas emissions. With more people utilizing personal mobility, air pollution is increasing the number of ARDS patients. Furthermore, the ARDS market is expected to rise due to lifestyle-related issues, growing healthcare infrastructure in developed countries, and increased knowledge about respiratory disorders.
Several risk factors, including alcohol abuse, chemotherapy, obesity, and low blood-protein levels, are contributing to the surge of ARDH cases. Furthermore, technological advances are projected to boost the acute respiratory distress syndrome market. One of the primary driving forces in the global ARDS market is the availability of suitable therapy and diagnostics for acute respiratory distress syndrome.
Moreover, pharmaceutical and biotech companies are collaborating with governments throughout the world to combat COVID-19. Approximately 115 vaccine candidates and 155 molecules are currently in the R&D pipeline. Furthermore, routinely used medications such as hydroxychloroquine have seen an enormous increase in demand for COVID-19 management. The rising demand for these treatments has created tremendous potential for manufacturers of COVID-19 management drugs, as many developed countries experienced a scarcity of these drugs. As a result of the demand for COVID-19 vaccines and treatment medications, the pharmaceutical and biotechnology sectors are predicted to increase significantly in the future. This is predicted to have a substantial influence on the ARDS market as well.
Acute respiratory distress syndrome (ARDS) is a fast progressing condition that affects critically ill people. The most serious consequence of ARDS is fluid leaking into the lungs, which makes breathing difficult or impossible.
Shortness of breath, cough, and fever are among ARDS symptoms; in certain cases, high heart rates and rapid breathing have also been observed. Patients with ARDS may have chest pain, particularly during inhalation, and some may also have blue nails and lips owing to drastically reduced oxygen levels in the blood.
Mechanical ventilation, prevention for stress ulcers and venous thromboembolism, nutritional assistance, and therapy of the underlying damage are all part of the acute respiratory distress syndrome treatment.
The ARDS causes are classified as either direct or indirect lung injuries. Pneumonia, aspiration, trauma, and others are direct lung injuries examples. Inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and pharmaceutical responses are examples of indirect lung injuries.
Leading pharma and MedTech companies such as MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, and others are currently working in the ARDS market.